What are the methods for eliminating gout tophi?

Gout tophi—also known as tophaceous deposits—are firm, chalky, subcutaneous nodules composed of monosodium urate (MSU) crystals that accumulate in soft tissues, cartilage, or bone due to chronic hyperuricemia. Their presence signifies longstanding, poorly controlled gout and reflects a high total body urate burden. Effective tophus reduction requires sustained, targeted urate-lowering therapy (ULT) aimed at achieving and maintaining a serum uric acid (sUA) level below the saturation point for MSU crystal formation—typically <6.0 mg/dL (<360 µmol/L), and often <5.0 mg/dL (<300 µmol/L) in patients with established tophi.

First-line pharmacologic ULT includes xanthine oxidase inhibitors such as allopurinol or febuxostat, titrated gradually to achieve target sUA levels while monitoring for adverse effects (e.g., allopurinol hypersensitivity syndrome, especially in HLA-B*58:01–positive individuals). In patients with renal impairment or intolerance to xanthine oxidase inhibitors, uricosurics like lesinurad (used in combination with a xanthine oxidase inhibitor) or probenecid may be considered—though probenecid is contraindicated in those with uric acid nephrolithiasis or moderate-to-severe chronic kidney disease. For refractory cases, pegloticase—a recombinant uricase enzyme that rapidly converts uric acid to allantoin—is indicated but requires careful patient selection, premedication to mitigate infusion reactions, and ongoing immunomonitoring due to high immunogenicity.

Nonpharmacologic strategies are essential adjuncts: lifelong adherence to a low-purine diet (limiting red meat, organ meats, shellfish, and sugar-sweetened beverages), avoidance of alcohol—particularly beer and spirits—maintenance of healthy body weight through gradual weight loss, and optimization of comorbidities such as hypertension, diabetes, and chronic kidney disease. Importantly, acute gout flares may increase during the initial months of ULT initiation; prophylactic anti-inflammatory therapy (e.g., low-dose colchicine, NSAIDs, or IL-1 inhibitors) is recommended for at least 6 months—or longer until tophi resolve and sUA remains stably suppressed.

While small tophi may regress completely with persistent urate-lowering, larger or long-standing deposits—especially those causing mechanical symptoms, joint deformity, nerve compression, or skin ulceration—may require surgical excision. However, surgery should never replace medical management; it is reserved for select cases after adequate ULT has been instituted and optimized, as recurrence is common without sustained sUA control. Regular clinical assessment—including serial physical examination, imaging (e.g., dual-energy CT for tophus volume quantification), and sUA monitoring—is critical to guide treatment intensity and evaluate response over time.